This may also explain why refractory EZH2GOF DLBCL cells, such as Karpas-422, respond slowly to EZH2 inhibition compared to HDAC1,2 inhibition (7 days for GSK126 versus 3 days for ACY-957) [8], as BBAP activity in these DLBCL cells might protect these cells from any DNA damage even in the absence of EZH2 activity. Here, HDAC1 is linked to diffuse large B-cell lymphoma.